HeartBeam Inc. to Discuss Q2 Results and Business Updates in August Conference Call

HeartBeam Inc. (NASDAQ: BEAT), a pioneer in medical technology aimed at revolutionizing cardiac care through personalized insights, has announced a conference call scheduled for August 13, 2025, at 4:30 p.m. Eastern Time. The call will focus on the company's second-quarter financial results for the period ending June 30, 2025, and will also cover updates on regulatory efforts, commercial readiness, and upcoming milestones. Leading the discussion will be CEO Robert Eno and CFO Timothy Cruickshank, who will also engage in a question-and-answer session with participants.

The significance of this event lies in HeartBeam's innovative approach to cardiac care, particularly its development of the first-ever cable-free 12-lead ECG system. This technology is designed to capture the heart's electrical signals in three dimensions, enabling portable devices to deliver actionable cardiac insights outside traditional medical facilities. Such advancements could significantly impact the management of cardiac health, offering physicians the tools to monitor heart conditions remotely and direct patients to appropriate care promptly.

HeartBeam's commitment to transforming cardiac care is further evidenced by its portfolio of 13 U.S. and 4 international patents related to its technology. For more details on HeartBeam's groundbreaking work, visit https://www.HeartBeam.com. Investors and interested parties can access the latest news and updates regarding BEAT at https://ibn.fm/BEAT.

This conference call represents a critical opportunity for stakeholders to gain insights into HeartBeam's financial health and strategic direction, underscoring the company's role in advancing cardiac care technology. The discussion will likely shed light on how HeartBeam plans to navigate the challenges and opportunities in the medical technology sector, particularly in the realm of remote cardiac monitoring and diagnostics.